For research use only. Not for therapeutic Use.
Linaprazan glurate inhibits exogenously or endogenously stimulated gastric acid secretion. Linaprazan glurate exhibits several advantageous properties, such as fast onset, high in vivo potency and/or long duration of action. Linaprazan glurate is useful in the research of gastrointestinal inflammatory diseases and peptic ulcer diseases (extracted from patent WO2010063876A1)[1].
| Catalog Number | I045104 |
| CAS Number | 1228559-81-6 |
| Synonyms | 5-[2-[[8-[(2,6-dimethylphenyl)methylamino]-2,3-dimethylimidazo[1,2-a]pyridine-6-carbonyl]amino]ethoxy]-5-oxopentanoic acid |
| Molecular Formula | C26H32N4O5 |
| Purity | ≥95% |
| InChI | InChI=1S/C26H32N4O5/c1-16-7-5-8-17(2)21(16)14-28-22-13-20(15-30-19(4)18(3)29-25(22)30)26(34)27-11-12-35-24(33)10-6-9-23(31)32/h5,7-8,13,15,28H,6,9-12,14H2,1-4H3,(H,27,34)(H,31,32) |
| InChIKey | GPHPBXRKAJSSIC-UHFFFAOYSA-N |
| SMILES | CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)NCCOC(=O)CCCC(=O)O |
| Reference | [1]. Mikael Dahlström, et al. Imidazopyridine derivatives which inhibit the secretion of gastric acid. Patent WO2010063876A1. |
